Clinical Trial Update: Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists [NA]

View source ↗

Summary

This clinical trial update reports safety and efficacy results comparing Thymoglobulin to IL-2 receptor antagonists (basiliximab) in patients with End Stage Ren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• Simulect (Basiliximab)
• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: Medical University of South Carolina | Conditions: End Stage Renal Disease | NA | Status: COMPLETED | Results posted: 2016-04-26